Cancer Detection, Diagnosis, and Treatment Technologies for Global Health (UH2/UH3)

The summary for the Cancer Detection, Diagnosis, and Treatment Technologies for Global Health (UH2/UH3) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Cancer Detection, Diagnosis, and Treatment Technologies for Global Health (UH2/UH3): This Funding Opportunity Announcement (FOA) is an initiative to support the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the FOA solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost devices or assays that are clinically comparable to currently used technologies for imaging, in vitro detection/diagnosis, prevention or treatment of cancers in humans living in LMICs.

Funds will be made available through the UH2/UH3 phased innovation cooperative agreement award mechanism. Applicants should have a working assay or prototype (not necessarily already capable of cancer applications). The initial UH2 exploratory phase will be a feasibility study to demonstrate technical functionality and clinical potential for use in LMIC settings by meeting specific performance milestones. UH2 projects that have met their milestones will be administratively considered by NCI and NIBIB and subsequently prioritized for transition to the UH3 validation phase. UH3 awards will support improvements and validations of the technologies in the LMIC settings. Projects proposed in response to this FOA will require multidisciplinary efforts to succeed and therefore all applicant teams must include expertise in engineering/assay/treatment development, oncology, global healthcare delivery, and business development. Investigators responding to this FOA must address both UH2 and UH3 phases.

Federal Grant Title:	Cancer Detection, Diagnosis, and Treatment Technologies for Global Health (UH2/UH3)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Education Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-CA-15-001
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.286, 93.394, 93.395
CFDA Descriptions:	Discovery and Applied Research for Technological Innovations to Improve Human Health; Cancer Detection and Diagnosis Research; Cancer Treatment Research
Current Application Deadline:	Mar 6, 2015
Original Application Deadline:	Mar 6, 2015
Posted Date:	November 24th, 2014
Creation Date:	Nov 24, 2014
Archive Date:	Apr 6, 2015
Total Program Funding:	$3,000,000
Maximum Federal Grant Award:	$1,000,000
Minimum Federal Grant Award:	none
Expected Number of Awards:	6
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Public housing authorities/Indian housing authorities
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Small businesses
Special district governments
Public and State controlled institutions of higher education
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
County governments
Private institutions of higher education
City or township governments
For profit organizations other than small businesses
Native American tribal organizations (other than Federally recognized tribal governments)
State governments
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Independent school districts
Native American tribal governments (Federally recognized)
Additional Information on Eligibility: Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-15-001.html
Grant Announcement Contact: NIH OER Webmaster [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

National Institutes of Health 301-496-3405
Similar Government Grants: • New Approaches for Measuring Brain Changes Across Longer Timespans (R01 Clinical Trial Opt...; • Enhancing Biomedical Engineering, Imaging, and Technology Acceleration (BEITA) at Historic...; • Understanding and Mitigating Health Disparities experienced by People with Disabilities ca...; • National Centers for Biomedical Imaging and Bioengineering (NCBIB) (P41 Clinical Trials Op...; • Research on Bioethical Issues Related to Bionic and Robotic Device Development and Transla...; • Exploratory Grants (P20) for NIBIB Quantum Projects; • Nibib Research Supplements to Promote Clinical Resident Research Experiences; • Innovation in Molecular Imaging Probes
More Grants from the National Institutes of Health: • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...; • NIDCR Predoctoral to Postdoctoral Transition Award to Promote a Diverse Dental, Oral and C...; • Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Am...